Literature DB >> 24399814

A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis.

S S Shaharir1, A H Abdul Ghafor, M S Mohamed Said, N C T Kong.   

Abstract

INTRODUCTION: Renal involvement is the most common serious complication in patients with systemic lupus erythematosus (SLE).
OBJECTIVE: The objective of this article is to investigate and determine the associated factors of disease damage among lupus nephritis (LN) patients.
METHODS: Medical records of LN patients who attended regular follow-up for at least one year in the Nephrology/SLE Clinic, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), were reviewed. Their Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index scores were noted. Univariate analysis and multivariable regression analysis were performed to determine the independent factors of disease damage in LN.
RESULTS: A total of 150 patients were included and their follow-up duration ranged from one to 20 years. Sixty (40%) LN patients had disease damage (SDI ≥1). In the univariate analysis, it was associated with age, longer disease duration, antiphospholipid syndrome (APS), higher maximum daily oral prednisolone dose (mg/day), lower mean C3 and C4, higher chronicity index and global sclerosis on renal biopsies (p < 0.05). Patients who received early (≤3 months after the SLE diagnosis) hydroxychloroquine (HCQ), optimum HCQ dose at 6.5 mg/kg/day and achieved early complete remission (CR) were less likely to have disease damage (p < 0.05). After adjustment for age, gender, disease duration and severity, multivariable regression analysis revealed that a higher maximum daily dose of oral prednisolone was independently associated with disease damage while early HCQ and CR were associated with lower disease damage.
CONCLUSION: Higher maximum daily prednisolone dose predicted disease damage whereas treatment with early HCQ and early CR had a protective role against disease damage.

Entities:  

Keywords:  Antiphospholipid syndrome; lupus nephritis; systemic lupus erythematosus

Mesh:

Substances:

Year:  2014        PMID: 24399814     DOI: 10.1177/0961203313518624

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

1.  Burden of Systemic Lupus Erythematosus on Work Productivity and Daily Living Activity: A Cross-Sectional Study Among Malaysian Multi-Ethnic Cohort.

Authors:  Fakhriah Abu Bakar; Syahrul Sazliyana Shaharir; Rozita Mohd; Mohd Shahrir Mohamed Said; Sakthiswary Rajalingham; Kong Wei Yen
Journal:  Arch Rheumatol       Date:  2020-02-07       Impact factor: 1.472

2.  Damage in the Multiethnic Malaysian Systemic Lupus Erythematosus (SLE) Cohort: Comparison with Other Cohorts Worldwide.

Authors:  Syahrul Sazliyana Shaharir; Heselynn Hussein; Sakthiswary Rajalingham; Mohd Shahrir Mohamed Said; Abdul Halim Abdul Gafor; Rozita Mohd; Ruslinda Mustafar
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

3.  Immunosuppressive effects of hydroxychloroquine and artemisinin combination therapy via the nuclear factor-κB signaling pathway in lupus nephritis mice.

Authors:  Ning Liang; Yanchun Zhong; Jie Zhou; Bihao Liu; Ruirui Lu; Yezhi Guan; Qi Wang; Chunlin Liang; Yu He; Yuan Zhou; Jianping Song; Jiuyao Zhou
Journal:  Exp Ther Med       Date:  2018-01-05       Impact factor: 2.447

4.  Serum uric acid is associated with damage in patients with systemic lupus erythematosus.

Authors:  Claudia Elera-Fitzcarrald; Cristina Reátegui-Sokolova; Rocio Violeta Gamboa-Cardenas; Mariela Medina; Francisco Zevallos; Victor Román Pimentel-Quiroz; Jorge Mariano Cucho-Venegas; José Alfaro-Lozano; Zoila Rodriguez-Bellido; Cesar Augusto Pastor-Asurza; Risto Alfredo Perich-Campos; Graciela S Alarcón; Manuel Francisco Ugarte-Gil
Journal:  Lupus Sci Med       Date:  2020-02-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.